Asthma/COPD Update with Inhaler Workshop

Size: px
Start display at page:

Download "Asthma/COPD Update with Inhaler Workshop"

Transcription

1 Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI

2 None Disclosures

3 Agenda Asthma Updates COPD Updates Inhaler Workshop

4 Medication Acronyms SABA: Short acting beta agonist LABA: Long acting beta agonist LAMA: Long acting muscarinic antagonist ICS: Inhaled corticosteroid

5 Asthma Updates

6 Asthma Updates SMART Trial aftermath Guidelines (GINA, ERS/ATS) FeNO testing Biologics

7 SMART Trial 2006: The Salmeterol Multicenter Asthma Research Trial Compared salmeterol vs. placebo added to usual care Subjects: 26,355 patients >12 years of age Nelson HS, Weiss ST, Bleeker ER, et al. The Salmeterol Multicenter Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest :

8 SMART Findings No significant difference between the two for: Overall safety Respiratory-related deaths (50 vs 36) Life-threatening experiences HOWEVER Nelson HS, Weiss ST, Bleeker ER, et al. The Salmeterol Multicenter Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest :

9 Salmeterol Is Evil Small increase in respiratory-related deaths (24 vs 11) Small increase in asthma-related deaths (13 vs 3) Majority were in African-Americans (20 vs 5) All were statistically significant So based on 15 more patients deaths with salmeterol from this subset population Nelson HS, Weiss ST, Bleeker ER, et al. The Salmeterol Multicenter Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest :

10 Innocent Bystanders

11 BELT Trial Evaluated tiotropium vs. LABA in addition to inhaled corticosteroids (ICS) in black population over 18 months Tiotropium + ICS (n = 532) LABA + ICS (n = 538) Weschler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs Long-Acting β-agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma. JAMA. October 27, (16):

12 BELT Findings No difference in clinical outcomes, including FEV 1 No significant difference with non-asthma and asthma-related adverse effects (P = 0.16) 3 deaths occurred, all in tiotropium group Weschler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs Long-Acting β-agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma. JAMA. October 27, (16):

13 AUSTRI Trial Evaluated safety of adding salmeterol to fluticasone in adults and adolescents (ages 12) Fluticasone only (n = 5834) Black (n = 856; 15%) Fluticasone + salmeterol (n = 5845) Black (n = 870; 15%) Stempel DA, Raphiou IH, Kral KM, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. NEJM. May 12, :

14 AUSTRI Findings Asthma exacerbations Fluticasone only (n = 597) Fluticasone + salmeterol (n = 480) Adding salmeterol reduced exacerbations 16-32% Asthma exacerbations in black patients Fluticasone only (n = 79) Fluticasone + salmeterol (n = 79) Stempel DA, Szefler SJ, Pederson S, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. NEJM. September 1, :

15 VESTRI Trial Evaluated safety of adding salmeterol to fluticasone in children (ages 4-11) Fluticasone only (n = 3101) Black (n = 511; 16.5%) Fluticasone + salmeterol (n = 3107) Black (n = 539; 17.3%) Stempel DA, Raphiou IH, Kral KM, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. NEJM. May 12, :

16 VESTRI Findings Asthma exacerbations Fluticasone only (n = 309) Fluticasone + salmeterol (n = 265) Asthma exacerbations in black patients Fluticasone only (n = 21) Fluticasone + salmeterol (n = 27) Stempel DA, Szefler SJ, Pederson S, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. NEJM. September 1, :

17 VESTRI Findings Serious asthma-related events Fluticasone only (n = 21) Fluticasone + salmeterol (n = 27) No deaths! Salmeterol + fluticasone is non-inferior to fluticasone alone Correlates to AUSTRI findings in children Stempel DA, Szefler SJ, Pederson S, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. NEJM. September 1, :

18 Is There A Class Effect? Salmeterol vindicated? What about formoterol? NEJM 9/1/2016: Evaluated safety of adding formoterol to budesonide (ages 12) Fluticasone only (n = 5766) Black (n = 407; 6.9%) Fluticasone + salmeterol (n = 5785) Black (n = 396; 6.8%) Peters SP, Bleeker ER, Canonica GW, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. NEJM. September 1, :

19 Study Findings Risk of asthma exacerbation Budesonide only (n = 633, 10.8%) Budesonide + formoterol (n = 539, 9.2%) Asthma-related deaths Budesonide only (n = 0) Budesonide + formoterol (n =2, <0.1%) Peters SP, Bleeker ER, Canonica GW, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. NEJM. September 1, :

20 Overall Findings No evidence that LABA on top of inhaled corticosteroid increases risk of asthma-related death No data on lone LABA compared to ICA or ICA + LABA

21 GINA 2017

22 GINA Stepwise Approach

23 GINA ICS

24 NAEPP Guidelines Classification National Asthma Education and Prevention Program: Expert panel report III Mild intermittent Mild persistent Moderate persistent Severe persistent Symptoms 2d/wk >2d/wk, not QD QD QD multiple times Nighttime awakenings 2x/mo 3-4x/mo >1x/wk, not nightly QD SABA use 2d/wk >2d/wk, not QD, not >1x/d QD QD multiple times Limitation None Mild Moderate Severe FEV 1 >80% >80% 60-80% <60%

25 ICD-10 Classification: Mild intermittent asthma: J45.2x Mild persistent asthma: J45.3x Moderate persistent asthma: J45.4x Severe persistent asthma: J45.5x Unspecified asthma: J45.90x Severity (x) Uncomplicated: 0 Exacerbation: 1 Status asthmaticus: 2

26 FeNO Fractional concentration of exhaled nitric oxide Modestly associated with eosinophilic airway inflammation Can be seen in other eosinophilic states w/o asthma Not elevated in neutrophilic asthma phenotype Decreased in smokers Does not help rule in or out asthma

27 FeNO cont. Recommended neither by GINA nor ERS/ATS ERS/ATS 2014: We suggest that clinicians do not use FeNO in addition to clinical criteria to guide therapy in adults or children with severe asthma (conditional recommendation, very low quality evidence). 1 GINA 2017: At present, neither sputum- nor FENOguided treatment is recommended for the general asthma population. (Evidence A) 2 1. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J : Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, Available from:

28 FeNO Interpretation: ICS Naïve

29 FeNO Interpretation: On ICS

30 Biologics In Asthma Omalizumab (Xolair ) Mepolizumab (Nucala ) Reslizumab (Cinqair )

31 Omalizumab Anti-IgE antibody For patients who failed ICS Baseline IgE IU/mL Limited information in treatment >700 IU/mL Note: 1 IU/mL = 2.5ng/mL

32 Omalizumab cont. Goal is to reduce IgE <10 IU/mL Cannot use IgE levels to monitor; levels increase due to IgE-anti-IgE complexes May take up to 1 year for IgE levels to decrease Issues: Anaphylaxis Questionable increased cancer risk Developed soon after starting therapy pre-existing?

33 Mepolizumab, Reslizumab Interleukin-5 (IL-5) antibody IL-5 responsible for differentiation and growth of eosinophils Mepolizumab Eosinophil count 150 cells/μl within 6 weeks of therapy Eosinophil count 300 cells/μl within past 12 months Reslizumab Eosinophil count 400 cells/μl

34 COPD Updates

35 COPD Updates GOLD 2017 Azithromycin in COPD Asthma-COPD overlap syndrome

36 GOLD 2017

37 GOLD Scales

38 GOLD ABCD

39 GOLD Treatment Algorithm

40 Azithromycin In COPD Macrolides have anti-inflammatory properties Evaluated number of exacerbations of azithromycin 250mg daily vs placebo (n = 1577) Placebo: 1.83 exacerbations/year Azithromycin: 1.48 exacerbations/year P = 0.01 Concern about QTc prolongation/cardiac issues Albert RK, Connett J, Baily WC, et al. Azithromycin for Prevention of Exacerbations of COPD. NEJM. August 25, (8):

41 Azithromycin & Cardiac Risk Cohort evaluated 3,546,239 patients between those who took: No antibiotics (n = 1,391,180) Amoxicillin (n = 1,348,672) Azithromycin (n = 347,795); over 5 days Ciprofloxacin (n = 246,626) Levofloxacin (n = 193,906) Ray WA, Murray KT, Hall K, et al. Azithromycin and the Risk of Cardiovascular Death. NEJM. May 17, (20):

42 Azithromycin & Cardiac Risk cont. Small increased risk of cardiovascular death with azithromycin (not significantly different from levofloxacin, but significantly greater than ciprofloxacin) Most pronounced in patients with underlying cardiovascular disease Ray WA, Murray KT, Hall K, et al. Azithromycin and the Risk of Cardiovascular Death. NEJM. May 17, (20):

43 Does Azithromycin Increase Risk? Different cohort from Denmark evaluated 2,204,469 azithromycin prescriptions compared to no antibiotic use and penicillin V No increased risk of cardiovascular death with azithromycin compared to penicillin In fact, penicillin had more cardiac deaths (146 vs. 17) and azithromycin had a -1 adjusted absolute risk of cardiac death

44 Asthma-COPD Overlap Continuum of obstructive diseases, not just separate entities Features of both COPD and asthma Asthma can have negative bronchodilator response COPD can have positive bronchodilator response Not defined by GINA or GOLD Multiple definitions by other organizations Postma DS and Rabe KF. The Asthma-COPD Overlap Syndrome. NEJM. September 24, (13):

45 One Attempt At Diagnosis Sin DD, Miravitlles M, Mannino D, et al. What is asthma-copd overlap syndrome? Towards a consensus statement from a round table discussion. Eur Respir J :

46 The Five Commandments 1) A patient with asthma may develop non-fully reversible airflow obstruction but this is not COPD, not even ACO; it is obstructive asthma. 2) A patient with asthma who smokes may also develop non-fully reversible airflow obstruction, which differs from obstructive asthma and from pure COPD. This is the most frequent type of patient with ACO. Miravitlles M. Diagnosis of asthma-copd overlap: the five commandments. Eur Respir J :

47 The Five Commandments 3) Some patients who smoke and develop COPD may have a genetic Th2 background (even in the absence of a previous history of asthma) and can be identified by high eosinophil counts in peripheral blood. These individuals could be included under the umbrella term of ACO. Miravitlles M. Diagnosis of asthma-copd overlap: the five commandments. Eur Respir J :

48 The Five Commandments 4) A patient with COPD and a positive bronchodilator test (>200 ml and >12% FEV 1 change) has reversible COPD but is not an asthmatic, or even ACO. 5) A patient with COPD and a very positive bronchodilator test (>400 ml FEV 1 change) is more likely to have some features of asthma and could also be classified as ACO. Miravitlles M. Diagnosis of asthma-copd overlap: the five commandments. Eur Respir J :

49 Inhaler Workshop

50 Inhaler Workshop Review currently available inhaled medications Discuss factors when selecting inhaled medication Critique currently available delivery devices Hands-on session

51 Inhaled Medications Beta (β 2 ) agonists Short acting Long acting Muscarnic (M 3 ) antagonists Short acting Long acting Inhaled corticosteroids

52 LAMA LABA Tiotropium (Spiriva ) HandiHaler : 9/24/04 Respimat : 9/24/14 Aclidinium (Tudorza ): 7/23/12 Umeclidinium (Incruse ): 4/30/14 Glycopyrrolate (Seebri ): 10/29/15 Salmeterol (Serevent ): 9/19/97 Arformoterol (Brovana ): 10/6/06 Formoterol (Perforomist ): 5/11/07 Indacaterol (Arcapta ): 7/1/11 Olodaterol (Striverdi ): 7/31/14

53 ICS Mometasone (Asmanex ) Twisthaler : 3/30/05 HFA: 4/25/14 Fluticasone Propionate (Flovent ) Diskus : 9/29/00 HFA: 5/14/04 Flunisolide (Aerospan ) 1/27/06 Budesonide (Pulmicort ) Respules : 8/8/00 Flexhaler : 7/12/06 Ciclesonide (Alvesco ): 1/10/08 Beclomethasone (Qvar ) HFA: 9//15/00 RediHaler : 8/3/17 Fluticaonse Furoate (Arnuity ): 8/20/14

54 LABA/ICS Salmeterol/Fluticasone Propionate (Advair ) Diskus : 8/24/00 HFA: 6/8/06 Formoterol/Budesonide (Symbicort ): 7/21/06 Formoterol/Mometasone (Dulera ): 6/22/10 Vilanterol/Fluticasone Furorate (Breo ): 5/10/13 LABA/LAMA Vilanterol/Umeclidinium (Anoro ): 12/18/13 Olodaterol/Tiotropium (Stiolto ): 5/21/15 Indacaterol/Glycopyrrolate (Utibron ): 10/29/15 Formoterol/Glycopyrrolate (Bevesepi ): 4/25/16 LABA/LAMA/ICS Vilanterol/Umeclidinium/Fluticasone Furorate (Trelegy ): 9/18/17

55 Discontinued inhalers Metaproterenol (Alupent ): 6/14/10 Triamcinolone (Azmacort ): 12/31/10 Pirbuterol (Maxair ): 12/31/13 Formoterol (Foradil ): 12/31/15 Nedocromil (Tilade ): 6/14/10 Cromolyn (Intal ): 12/31/10

56 Goals for Inhalation Deliver drug to respiratory mucosa Minimize systemic absorption

57 Factors Affecting Delivery Drug/formulation-related Device-related Patient/disease-related Thorrson, L and Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: Focus on budesonide. Resp Med. July, (7);

58 Drug/Formulation Issues Drug potency Pharmacokinetics Particle size Propellant Additives Viscosity Thorrson, L and Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: Focus on budesonide. Resp Med. July, (7):

59 Device Issues Deposition properties Particle size Ease of use Accuracy of dosage Administration apparatus Thorrson, L and Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: Focus on budesonide. Resp Med. July, (7):

60 Patient/Disease Issues Inspiratory flow rate Upper airway anatomy Lower airway obstruction Ability to use device Competency Cost Patient preference & adherence Thorrson, L and Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: Focus on budesonide. Resp Med. July, (7):

61 Remember This?

62 Chlorofluorocarbons (CFCs) Used as propellants in aerosols Also refrigerants and solvents Destroyed ozone layer Montreal Protocol on Substances that Deplete the Ozone Layer September 16, 1987 Phase out CFCs

63 Inhalers: Ozone Killers! FDA phased out generic albuterol as of 12/31/2008 Newer albuterol products use hydrofluoroalkane (HFA) Available then as now: ProAir HFA Proventil HFA Ventolin HFA $$$ and still no generics Accessed October 2, 2017

64 The Only Good Casualty

65 Delivery Systems Diskus Ellipta Flexhaler HandiHaler RespiClick Respimat HFA Nebulizer NeoHaler Pressair

66 Diskus Flovent Fluticasone propionate Serevent Salmeterol Advair Fluticasone propionate + Salmeterol

67 Ellipta Arnuity Fluticasone furoate Incruse Umeclidinium Anoro Umeclidinium + Vilanterol Breo Fluticasone furoate + Vilanterol Trelegy Fluticasone furoate + Vilanterol + Umeclidinium

68 Flexhaler Pulmicort Budesonide

69 HandiHaler Spiriva Tiotropium

70 NeoHaler Arcapta Indacaterol Seebri Glycopyrrolate Utibron Indacaterol + Glycopyrrolate

71 Pressair Tudorza Aclidinium

72 RespiClick ProAir Albuterol

73 Respimat Spiriva Tiotropium Striverdi Olodaterol Stiolto Tiotropium + Olodaterol Combivent Albuterol + Ipratropium

74 HFA ProAir Albuterol Proventil Albuterol Ventolin Albuterol Xopenex Levalbuterol

75 Nebulizer Albuterol Ipratropium DuoNeb Albuterol + Ipratropium Brovana Arformoterol Perforomist Formoterol Pulmicort Respules Budesonide

76 Device Selection Summary Chose drug(s) Based on GINA/GOLD guidelines Clinical history Dosing regimen Chose delivery system Is patient able to use it physically? Mental competence? Is it covered by insurance?

77 Why Care About Teaching? You can get paid for it! CPT: Document! My example: I personally instructed the patient on the use of [Inhaler Name]. Appropriate technique was demonstrated. Questions answered. Sample provided to patient.

78 The End Thank you for your time!

Asthma/COPD Update with Inhaler Workshop

Asthma/COPD Update with Inhaler Workshop Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

FASENRA (benralizumab)

FASENRA (benralizumab) FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Select Inhaled Respiratory Agents

Select Inhaled Respiratory Agents Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the

More information

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

STRIVERDI RESPIMAT (olodaterol hcl) aerosol STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications

More information

MDI Bonanza. Dwayne Griffin, DO

MDI Bonanza. Dwayne Griffin, DO MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

reslizumab (Cinqair )

reslizumab (Cinqair ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power

More information

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18 Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary

Three s Company - The role of triple therapy in chronic obstructive pulmonary Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients

Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution

More information

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS:

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 12/14/2017 CLASS: LOB: Respiratory Disorders Medi-Cal REVIEW HISTORY (MONTH/YEAR) 12/17,12/16, 5/15,

More information

End Stage COPD Guidance Document

End Stage COPD Guidance Document End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for

More information

Asthma COPD Update 2018

Asthma COPD Update 2018 Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State

More information

Diagnosis and Management of Asthma

Diagnosis and Management of Asthma Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:

More information

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE

REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly

More information

Michelle Zeidler, MD, MS

Michelle Zeidler, MD, MS 7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA

More information

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol) Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:

More information

Cinqair (reslizumab injection for intravenous use)

Cinqair (reslizumab injection for intravenous use) Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives

Asthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor

More information

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy

More information

Test Your Inhaler Knowledge

Test Your Inhaler Knowledge A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary

More information

Individualizing and Optimizing Asthma Care. CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas

Individualizing and Optimizing Asthma Care. CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas Individualizing and Optimizing Asthma Care CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas Speaker Disclosure Dr. Hawkins has disclosed that he has no actual or potential

More information

Pulmonary Medication Toolkit: Is yours up to date?

Pulmonary Medication Toolkit: Is yours up to date? Pulmonary Medication Toolkit: Is yours up to date? Michelle Schymik, PharmD, BCPS Pharmacist for Deaconess Health System Overview Assuming basic knowledge of pulmonary diseases FEEL FREE TO ASK ME ANY

More information

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP? 10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher

More information

benralizumab (Fasenra )

benralizumab (Fasenra ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

Foundations of Pharmacology

Foundations of Pharmacology Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids

More information

The Latest Medications A Pharmacological Update for RTs

The Latest Medications A Pharmacological Update for RTs The Latest Medications A Pharmacological Update for RTs Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Georgia State University Objectives

More information

COPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center

COPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC

More information

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida

First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction

More information

Key features and changes to these four components of asthma care include:

Key features and changes to these four components of asthma care include: Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding

More information

New and Novel Medications for Respiratory Care

New and Novel Medications for Respiratory Care New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

Take My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care

Take My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe

More information

Balanced information for better care. Helping patients with COPD breathe easier

Balanced information for better care. Helping patients with COPD breathe easier Balanced information for better care Helping patients with COPD breathe easier COPD is the third-leading cause of death in the U.S., following cancer and heart disease 1 FIGURE 1. Women now have a higher

More information

4/3/2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018

4/3/2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018 Approach to treatment List of medication Abbreviations When to use medications Pharmokinetics Pharmacodynamics Step wise therapy both for acute and chronic

More information

Provider Respiratory Inservice

Provider Respiratory Inservice Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines

More information

Nucala (mepolizumab injection for subcutaneous use)

Nucala (mepolizumab injection for subcutaneous use) Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Quality Department Guidelines for Clinical Care Ambulatory COPD Guideline Team Team Leader Davoren A Chick, MD General Medicine Team Members Paul J Grant, MD General Medicine R Van Harrison, PhD Learning

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy

More information

Objectives. Speaker has no relationship to disclose. Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis,

Objectives. Speaker has no relationship to disclose. Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis, Sneezes, Wheezes, and Respiratory Diseases: An update on Asthma, Allergic Rhinitis, and COPD Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates Objectives Evaluation of medications,

More information

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic

More information

Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma

Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care

More information

Improving Outcomes in COPD

Improving Outcomes in COPD Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea

More information

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives. Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate

More information

Pharmacist CE LESSON. Breathe easy: with asthma/copd 1 MAY 2016

Pharmacist CE LESSON. Breathe easy: with asthma/copd 1 MAY 2016 to this lesson. By Clark Kebodeaux, Pharm.D., BCACP, assistant professor pharmacy practice and science, University of Kentucky College of Pharmacy Author Disclosures: Clark Kebodeaux and the DSN editorial

More information

UPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER

UPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER UPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA OBJECTIVES Describe Describe asthma medications that have been added

More information

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial

More information

Proposed Preferred Drug List. Clinical Criteria

Proposed Preferred Drug List. Clinical Criteria Proposed Preferred Drug List with Clinical Criteria Proposal for TennCare February 7, 2008 Page 1 of 87 PDL Decision Process The primary clinical decision that needs to be made is determining if the drugs

More information

COPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed?

COPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed? Understanding COPD The Mount Sinai National Jewish Health Respiratory Institute was formed by the nation s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic

More information

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

MANAGING ASTHMA. Nancy Davis, RRT, AE-C MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma

More information

THE COPD PRESCRIBING TOOL

THE COPD PRESCRIBING TOOL THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their

More information

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and

More information

continuing education for pharmacists

continuing education for pharmacists continuing education for pharmacists Volume XXXIV, No. 12 Asthma: Approaches to Treatment and New Therapies Cortney M. Mospan, PharmD, BCACP, CGP, Assistant Professor of Pharmacy, Wingate University School

More information

Take My Breath Away COPD Update. Take My Breath Away COPD Update 4/16/16. Juliann Horne, PharmD, PhC, BCACP

Take My Breath Away COPD Update. Take My Breath Away COPD Update 4/16/16. Juliann Horne, PharmD, PhC, BCACP Take My Breath Away COPD Update Juliann Horne, PharmD, PhC, BCACP jmhorne@salud.unm.edu April 16, 2016 Take My Breath Away COPD Update Juliann Horne, PharmD, PhC, BCACP jmhorne@salud.unm.edu April 16,

More information

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.

More information

University System of Georgia Prior Authorization, Step Therapy and Quantity Limit List (Updated 1/1/2016)

University System of Georgia Prior Authorization, Step Therapy and Quantity Limit List (Updated 1/1/2016) University System of Georgia, Step Therapy and Quantity Limit List (Updated 1/1/2016) (PA) Your doctor will need to obtain a prior authorization for the drugs listed below, before your prescription drug

More information

Class Update: Asthma / COPD Medications

Class Update: Asthma / COPD Medications Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Common Inhaled Asthma Medications Dose Comparison and Tips for Use

Common Inhaled Asthma Medications Dose Comparison and Tips for Use Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications

More information

Respiratory Medications and Devices Update 2/15

Respiratory Medications and Devices Update 2/15 Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient

More information

Management of COPD Updates and Evidence

Management of COPD Updates and Evidence Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif

More information

Inhaled Corticosteroid Dose Comparison in Asthma

Inhaled Corticosteroid Dose Comparison in Asthma This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides

More information

Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION

Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management

More information

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma

More information

COPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS

COPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was

More information

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Commissioner for the Department for Medicaid Services Selections for Preferred Products Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at

More information

A Patient s Guide to Aerosol Medication Delivery

A Patient s Guide to Aerosol Medication Delivery A Patient s Guide to Aerosol Medication Delivery 3rd Edition Prepared by: Tim Op t Holt, EdD, RRT, AE-C, FAARC Kimberly Wiles, RRT, CPFT Ellen Becker, PhD, RRT, RRT-NPS, RPFT, AE-C, FAARC Edited by: Timothy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32

More information

Pulmonary Disease Aerosol Delivery Devices A Guide for Physicians, Nurses, Pharmacists, and Other Health Care Professionals

Pulmonary Disease Aerosol Delivery Devices A Guide for Physicians, Nurses, Pharmacists, and Other Health Care Professionals Pulmonary Disease Aerosol Delivery Devices A Guide for Physicians, Nurses, Pharmacists, and Other Health Care Professionals 3rd Edition Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC Lori Wilken, PharmD,

More information

He is still Short of Breath Is there any new puffer? Saidul Ansary

He is still Short of Breath Is there any new puffer? Saidul Ansary He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,

More information

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017 GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and

More information

A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD

A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD Chris Federico PharmD, BCACP RIPF Kimberly McDonough Spring Seminar May 4, 2016 Disclosure I have no actual

More information

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers

More information

Wirral COPD Prescribing Guidelines

Wirral COPD Prescribing Guidelines Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR

More information

Update on Pulmonary Diseases. Jeffrey Lessar, MD

Update on Pulmonary Diseases. Jeffrey Lessar, MD Update on Pulmonary Diseases Jeffrey Lessar, MD 1 No disclosures to make No conflicts 2 Goals Update on key changes in Pulmonary Therapy 3 Spirometry Spirometry FEV1- forced expiratory Volume in 1 Sec

More information

Your Inhaler Devices & You

Your Inhaler Devices & You 1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE

More information